🟢 Chemours is trading 4.3% up today as materials-sector strength supports recovery

Chemours is trading at $15.21 (+4.25%) as materials-sector strength supports the recovery after its earnings-driven selloff.

• August 5’s 18.63% decline followed Q2 earnings disappointment: revenue of $1.59 billion missed estimates, while adjusted EPS was $0.42 versus $0.50 expected.
• Management reduced full-year adjusted EBITDA guidance to $775 million–$825 million.
• XLB is up 1.68%; no fresh company-specific catalyst was identified.